Business Description
Senhwa Biosciences Inc
ISIN : TW0006492002
Description
Senhwa Biosciences Inc is engaged in the development of new drugs and special pharmaceutical ingredients focusing on human efficacy. The company's product pipeline includes Pidnarulex (CX-5461), Silmitasertib (CX-4945), and Silmitasertib (for Moderate Covid-19). All of its revenue comes from Taiwan.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 59.73 | |||||
| Equity-to-Asset | 0.97 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.07 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 77.22 | |||||
| Beneish M-Score | -2.71 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 11.2 | |||||
| 3-Year EBITDA Growth Rate | 10.2 | |||||
| 3-Year EPS without NRI Growth Rate | 9.6 | |||||
| 3-Year FCF Growth Rate | 1.9 | |||||
| 3-Year Book Growth Rate | -17.1 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 35.94 | |||||
| 9-Day RSI | 42.3 | |||||
| 14-Day RSI | 45.26 | |||||
| 6-1 Month Momentum % | 25.51 | |||||
| 12-1 Month Momentum % | -11.78 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 48.44 | |||||
| Quick Ratio | 48.44 | |||||
| Cash Ratio | 47.24 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.2 | |||||
| Shareholder Yield % | 0.02 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 54.8 | |||||
| Operating Margin % | -30570.1 | |||||
| Net Margin % | -29153.8 | |||||
| FCF Margin % | -28205.7 | |||||
| ROE % | -21.95 | |||||
| ROA % | -21.41 | |||||
| ROIC % | -898.74 | |||||
| 3-Year ROIIC % | -21028.08 | |||||
| ROC (Joel Greenblatt) % | -1331.23 | |||||
| ROCE % | -21.69 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 4133.34 | |||||
| PB Ratio | 3.73 | |||||
| Price-to-Tangible-Book | 3.73 | |||||
| EV-to-EBIT | -11.31 | |||||
| EV-to-EBITDA | -11.78 | |||||
| EV-to-Revenue | 3276.14 | |||||
| EV-to-FCF | -11.74 | |||||
| Price-to-Net-Current-Asset-Value | 3.81 | |||||
| Price-to-Net-Cash | 3.91 | |||||
| Earnings Yield (Greenblatt) % | -8.84 | |||||
| FCF Yield % | -6.38 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Senhwa Biosciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 1 | ||
| EPS (TTM) (NT$) | -3.26 | ||
| Beta | 0.68 | ||
| Volatility % | 48.59 | ||
| 14-Day RSI | 45.26 | ||
| 14-Day ATR (NT$) | 2.036343 | ||
| 20-Day SMA (NT$) | 50.525 | ||
| 12-1 Month Momentum % | -11.78 | ||
| 52-Week Range (NT$) | 40.35 - 64.5 | ||
| Shares Outstanding (Mil) | 89.19 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Senhwa Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Senhwa Biosciences Inc Stock Events
| Event | Date | Price(NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Senhwa Biosciences Inc Frequently Asked Questions
What is Senhwa Biosciences Inc(ROCO:6492)'s stock price today?
The current price of ROCO:6492 is NT$49.60. The 52 week high of ROCO:6492 is NT$64.50 and 52 week low is NT$40.35.
When is next earnings date of Senhwa Biosciences Inc(ROCO:6492)?
The next earnings date of Senhwa Biosciences Inc(ROCO:6492) is .
Does Senhwa Biosciences Inc(ROCO:6492) pay dividends? If so, how much?
Senhwa Biosciences Inc(ROCO:6492) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers